Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Xalkori

Crizotinib

RLDNDA 202570 2 strengths Pf Prism Cv
Approved
Aug 26, 2011
Strengths
2
Listed patents
3
Applications
2

What does the FDA Orange Book show for Xalkori?

Xalkori contains Crizotinib and appears in 2 FDA Orange Book applications. NDA 202570 is the lead filing, with 2 presentations shown in detail; the other exact-name filings are listed separately. The page preserves strength, dosage form, route, status, RLD/RS, TE, patent, and exclusivity facts. Clinical labeling requires an exact application-matched source.

FDA applications
2; lead NDA 202570

Every filing shown uses the exact FDA product name; the lead filing supplies the detailed presentation view.

Lead application holder
Pf Prism Cv

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
2

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
None posted

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
3

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
2

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
001200MGCAPSULEORALPrescriptionNone posted
RLD
002250MGCAPSULEORALPrescriptionNone posted
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Pf Prism Cv

The Orange Book identifies this organization as the applicant responsible for NDA 202570.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

2 presentations listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

3 listed patent expirations and 2 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Nov 06, 2029. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

0 other ANDAs and 0 other NDAs found

0 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 202570 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Capsule · Oral

Crizotinib

1 application
Product rows
2
Active applications
1
Active with AB row
0

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-202570

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Strengths & dosage forms

2 approved presentations · NDA 202570
RLD
Strength
200MG
Dosage form
CAPSULE
Route
ORAL
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    15 yr 2 mo ago

  2. Today

  3. Patent 7825137 expires

    Listed method-of-use patent (U-3403) expiration.

    in 10 mo

  4. Patent 7825137 expires

    Listed method-of-use patent (U-3058) expiration.

    in 10 mo

  5. Patent 7825137 expires

    Listed method-of-use patent (U-3057) expiration.

    in 10 mo

  6. Exclusivity ends · ODE-328

    Orphan-drug exclusivity (7 years)

    in 1 yr 6 mo

  7. Exclusivity ends · ODE-407

    Orphan-drug exclusivity (7 years)

    in 3 yr

  8. Patent 7858643 expires

    Listed drug substance patent expiration.

    in 3 yr 3 mo

  9. Patent 8217057 expires

    Listed drug substance patent expiration.

    in 3 yr 4 mo

Patent & exclusivity timeline

Protection horizon
20262027202820292030TodayPatent 7825137: 2027-05-12Patent 7825137Patent 7825137: 2027-05-12Patent 7825137Patent 7825137: 2027-05-12Patent 7825137Exclusivity ODE-328: 2028-01-14Exclusivity ODE-328Exclusivity ODE-407: 2029-07-14Exclusivity ODE-407Patent 7858643: 2029-10-08Patent 7858643Patent 8217057: 2029-11-06Patent 8217057
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

CRIZOTINIB

Strength

200MG

Dosage form

CAPSULE

Route

ORAL

TE code

Not listed

Application

NDA 202570

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Marketing exclusivity

Hatch-Waxman
  • ODE-328Orphan-drug exclusivity (7 years)

    in 1 yr 6 mo

  • ODE-407Orphan-drug exclusivity (7 years)

    in 3 yr

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7825137in 10 mo
U-3403
7825137in 10 mo
U-3058
7825137in 10 mo
U-3057
7858643in 3 yr 3 mo
SubstanceProduct
8217057in 3 yr 4 mo
SubstanceProduct

Other FDA applications for Xalkori

1 additional filing

The FDA has approved 2 separate applications under this product name. Each row is one application: a distinct applicant and approval for the same drug.

Other FDA applications approved under the product name Xalkori, with applicant, approval date, number of strengths, therapeutic-equivalence code, and marketing status.
ApplicationApplicantApprovedStrengthsTE codeStatus
NDA 217581Pf Prism CvSep 07, 20233—Prescription

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

No other applications share this active ingredient.

View full Crizotinib family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Xalkori: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 202570 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo